T he peroxisome proliferatoractivated receptor (PPAR)-␥ is a member of the nuclear hormone receptor family of transcription factors and is highly expressed in human adipose tissue (1). This suggests that adipose tissue is the primary target for PPAR-␥ agonists. PPAR-␥ transcriptional activity is regulated by nutritional factors, cytokines, and cofactor assembly. Several investigators have identified a pivotal role for PPAR-␥ in fat cell differentiation, lipid storage, vascular function, and energy metabolism (2,3). PPAR-␥ is alternately spliced to generate two isoforms: PPAR-␥1 and -␥2; but PPAR-␥1 is the major form existing in the adipose tissue (4). PPAR-␥ is activated by specific, naturally occurring ligands including polyunsaturated fatty acids and prostaglandin J2 derivatives. However, there are a number of synthetic compounds that also activate this receptor. Thiazolidinediones (TZDs) are a pharmacological insulin-sensitizing class of compounds that are high-affinity ligands for PPAR-␥ and widely used for treatment of type 2 diabetes (5,6).
The antidiabetic effect of TZDs is well established, although the precise mechanism of action is unknown. Chronic treatment with PPAR-␥ activators (e.g., pioglitazone, rosiglitazone) improves glucose homeostasis by increasing insulin sensitivity in various animal models of obesity and diabetes as well as in humans (7, 8) . However, several studies have observed a modest weight gain in diabetic subjects treated with TZDs (9). Diabetic patients treated with TZDs have increased subcutaneous adipose tissue and decreased or unchanged visceral adipose tissue (10). One mechanistic hypothesis used to explain the insulin-sensitizing effect of TZDs includes the differentiation of mesenchymal and preadipocytic precursors in adipose tissue (i.e., adipose tissue remodeling), exemplified by an increase in the number of small adipocytes and a shift in lipids from large adipocytes into new small more insulin-sensitive adipocytes (11) . Small adipocytes may be more efficient at storing lipids, and body weight could increase as a result. This might also reduce the production of harmful adipocytokines such as tumor necrosis factor-␣ or resistin. Alternate mechanisms, including a reduction in circulating free fatty acids, have been proposed as a link between TZDs and improved insulin sensitivity. A reduction in free fatty acids is observed early after PPAR-␥ acti-vation and occurs before plasma glucose and triglycerides fall (12) .
In humans, triglyceride storage occurs mainly by coupling existing fatty acids to glycerol-3-phosphate; de novo fatty acid synthesis makes also a significant contribution (13) . The activation of PPAR-␥-responsive genes could increase body fat by increasing the genes that facilitate either or both of these processes. As genes that produce enzymes involved directly or indirectly in the formation of glycerol-3-phosphate, we selected the genes for glycerol kinase (GyK), glycerol-3-phosphate dehydrogenase (GPDH), PEPCK-C, and c-Cbl-associated protein (CAP). As examples of genes involved in the supply of fatty acids, we selected lipoprotein lipase (LPL), fatty acid synthase (FAS), and acetyl-CoA synthetase (ACS). We hypothesize that the activation of PPAR-␥-responsive genes in one or more of these pathways will account for the carbon skeletons that make the extra triglyceride for storage in fat cells.
Thus, the aim of this study was to relate the expression of PPAR-␥-responsive genes in adipose tissue to the expression of PPAR-␥ and to define the effect of pioglitazone to regulate these same genes in patients with type 2 diabetes.
RESEARCH DESIGN AND
METHODS -Forty-eight men and women with type 2 diabetes were enrolled in a clinical trial to determine the effect of pioglitazone on body composition (22 men and 26 women, mean age 54.7 Ϯ 9.5 years, BMI 32.1 Ϯ 5.1 kg/m 2 ). Diabetes was defined by a fasting plasma glucose Ն126 mg/dl at entry or fasting plasma glucose Ͼ115 mg/dl and a 2-h oral glucose tolerance test glucose Ն200 mg/dl or current use of either metformin or sulfonylureas. Fasting plasma glucose at entry had to be Յ200 mg/dl. Insulin and triglyceride concentrations were 14.70 Ϯ 9.36 mIU/ml and 213.88 Ϯ 112.14 mg/dl, respectively.
Patients were excluded if they had significant renal, cardiac, liver, lung, or neurological disease. Also, if patients were taking drugs known to affect lipid metabolism, energy metabolism, or body weight, such as orlistat, sibutramine, ephedrine, phenylpropanolamine (Dexatrim), or corticosteroids, they were excluded. All patients signed a consent form approved by the Pennington Biomedical Research Center Ethical Review Board after risks and procedures had been explained. During the 24-week trial, subjects received the usual care for their diabetes, with instruction on a healthy diabetic diet by a dietitian.
All subjects were randomly divided into two groups: placebo and pioglitazone (24 patients in each group). Pioglitazone and matching placebo groups were prepared by Takeda Pharmaceuticals and were given as a single daily dose of 30 mg/day or placebo each morning for 12 weeks. The dose of pioglitazone was increased to 45 mg/day at week 8 if the fasting plasma glucose was Ͼ100 mg/dl or the HbA 1c was Ն7.0%.
Subcutaneous adipose tissue was obtained by Bergstrom needle biopsies of subcutaneous adipose tissue 6 -10 cm lateral to the umbilicus at baseline and after 12 weeks of treatment following an overnight fast as previously described (14) . Fat samples were cleaned of visible connective tissue and blood vessels under a bright light, immediately frozen in liquid nitrogen, and then stored at Ϫ70°C until assays.
RNA extraction and real-time RT-PCR Total RNA from 50 -100 mg of adipose tissue was isolated with Trizol reagent (Invitrogen, Carlsbad, CA) as previously described (14) , quantified spectrophotometrically, and the integrity of the RNA confirmed by PAGE with Sybr green detection.
Real-time RT-PCRs were performed in a 50-l final volume using a Taqman 100Rxn PCR Core Reagent Kit (Applied Biosystems, Roche, Branchburg, NJ). Ten microliters of RNA was mixed with 40 l of Taqman Universal Master Mix (5 l of 10ϫ buffer A; 11 l of 25 mmol/l MgCl 2 ; 1 l of each dNTP; 0.25 l of reverse transcriptase; 0.25 l of RNase inhibitor; 0.25 l of AmpliTaq Gold DNA polymerase; and 15.25 l of water). The concentration of the PCR primers was 300 -450 nmol/l and the fluorogenic probes 100 -200 nmol/l (depending on the gene). Taqman probes (complementary to the genes of interest, labeled with FAM [6-FAM, 6-carboxyfluorescein] dye) and primers were designed using Primer Express Software, version 2.0 (Applied Biosystems). The sequences of primers and probes and accession numbers for each gene are listed in Table 1 . Real-time RT-PCR was carried out in duplicate for each sample in optical 96-well reaction plates in an ABI PRISM 7700 sequence detector (Applied Biosystems) using the following parameters: one cycle of 48°C for 30 min, then 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. All expression data were normalized by dividing the amount of target by the amount of cyclophilin used as internal control. The specificity of the PCR product for each tested gene was confirmed by gel electrophoresis.
Statistical analysis
All clinical data were entered into the Pennington Biomedical Research Center database, extracted, and combined with a gene expression database and analyzed using JMP version 5.0.1a (SAS, Cary, NC). Correlations were performed in a pairwise fashion using the Pearson product-moment statistic. Two-way ANOVA was performed using time and treatment as factors to assess changes in gene expression within subject during the study. All values are presented in figures and tables as sample (raw) means Ϯ SE. Significant differences were assumed for P Յ 0.05.
RESULTS

Subjects
As previously reported, the body weight of patients treated with pioglitazone increased by 1.68 Ϯ 2.4 and 3.68 Ϯ 3.11 kg at 12 and 24 weeks, respectively (P Ͻ 0.001). The body weight of the placebotreated patients decreased slightly at each time point (Ϫ0.71 Ϯ 2.19 and Ϫ0.70 Ϯ 3.3 kg at 12 and 24 weeks, respectively) (15) . Body fat measured by dual-energy X-ray absorptiometry rose 3.55 Ϯ 2.52 kg over the 24 weeks and accounted for almost all of the increase in body weight in the pioglitazone-treated patients. Body fat in this group increased in the arms, legs, and abdomen but not in the visceral fat compartment (15) .
Genes involved in glycerol-3-phosphate synthesis Expression for three of the four genes in this group was increased by treatment with pioglitazone ( Fig. 1A-D) . The mRNA level of PEPCK-C was increased significantly to 1.07 Ϯ 0.10 arbitrary units in the pioglitazone-treated group compared with 0.59 Ϯ 0.09 in the placebo-treated group (P Ͻ 0.01) (Fig. 1A) . The mRNA for GPDH was 1.46 Ϯ 0.07 in the TZDtreated group, which was significantly higher than the 1.13 Ϯ 0.07 seen in the placebo-treated group (P Ͻ 0.01) (Fig.  1B) . In contrast, there was no difference between the two treatment groups in the mRNA for GyK (0.39 Ϯ 0.03 vs. 0.37 Ϯ 0.03 in the TZD-vs. placebo-treated group) (Fig. 1C) . The expression of CAP, a signaling protein involved in insulinstimulated glucose transport, was markedly stimulated by pioglitazone (4.31 Ϯ 0.29 vs. 2.64 Ϯ 0.28; P Ͻ 0.0001) (Fig.  1D) .
Genes involved in fatty acid metabolism, synthesis, or storage The mRNA expression for LPL was 1.14 Ϯ 0.07 in the pioglitazone-treated patients and was significantly higher than the 0.74 Ϯ 0.06 arbitrary units in the placebo-treated group (P Ͻ 0.001) (Fig. 1E) . The mRNA for ACS was also significantly higher in the pioglitazone-treated patients than in the placebo-treated control subjects (1.63 Ϯ 0.12 vs. 0.94 Ϯ 0.11; P Ͻ 0.001) (Fig. 1F) . FAS mRNA expression tended to increase in the pioglitazone-treated patients (5.42 Ϯ 0.54 vs. 3.67 Ϯ 0.51; P ϭ 0.09) (Fig. 1G) .
Expression of other "TZD responsive" genes The mRNA expression levels for tumor necrosis factor-␣, leptin, and resistin, three adipocytokines, were not affected by treatment with pioglitazone and did not differ between the two groups (data not shown). Furthermore, no changes were observed between these two groups in angiopoietin like-4 (ANGPTL-4, also known as PGAR) and 11-␤-hydroxysteroid dehydrogenase type 1 (11␤ HSD 1) mRNA.
Correlations with the expression of PPAR-␥1/PPAR-␥2
The baseline PPAR-␥1 mRNA was significantly correlated with mRNA for LPL ( Fig. 2A) , CAP (Fig. 2B) , ACS (Fig. 2C) , 11␤ HSD 1 (Fig. 2D) , GyK (Fig. 2E) , FAS (r ϭ 0.33; P Ͻ 0.05; data not shown), leptin (r ϭ 0.32; P Ͻ 0.05), and GPDH (r ϭ 0.29; P Ͻ 0.05). The expression of PPAR-␥2 was significantly correlated with LPL (r ϭ 0.70; P Ͻ 0.001; data not shown), CAP (r ϭ 0.48; P Ͻ 0.001), PEPCK-C (r ϭ 0.39; P Ͻ 0.01), leptin (r ϭ 0.44; P ϭ 0.01), and GPDH (r ϭ 
Figure 1-Effect of the 12-week treatment with pioglitazone or placebo on PEPCK-C (A), GPDH (B), GyK (C), CAP (D), LPL (E), ACS (F), FAS (G), and ANGPTL-4 (H).
0.36; P Ͻ 0.05) but not with the other tested genes. The expression of mRNA for FAS was highly correlated with ACS ( Fig. 2G) and GPDH (Fig. 2H) . Additionally, the mRNA for ACS was correlated with GPDH ( Fig. 2I) .
Treatment with pioglitazone did not change the mRNA levels of the two tested isoforms of PPAR-␥ (PPAR-␥1 or PPAR-␥2) in adipose tissue. The PPAR-␥ protein expression was determined by a Western blotting with an antibody that recognizes a region common to PPAR-␥1 and PPAR-␥2 isoforms and did not show any major differences in PPAR-␥ protein content before versus after TZD treatment (data not shown).
There was no significant correlation between the change in the expression of the lipogenic genes and the change in body weight or body fat after TZD treatment. The expression of PPAR-␥1 was inversely related to the fasting insulin value (P Ͻ 0.01). However, the slopes were not different across sexes. Interestingly, men had higher insulin values for any given level of PPAR-␥1 gene expression (P Ͻ 0.05).
CONCLUSIONS -The antidiabetic
TZDs have revolutionized the pharmacotherapy of diabetes. TZDs as ligands for the PPAR-␥ nuclear hormone receptors exert pleuripotent effects on many cell types (6,16). The aim of this study was to define the effect of TZDs to alter transcription of lipogenic and lipid storage genes in adipose tissue in vivo. There are several notable findings from our study of gene expression in adipose tissue from diabetic subjects treated with pioglitazone. First, we measured the expression of these same genes before and after 12 weeks' treatment with TZD or placebo. We measured gene expression at this time point to be certain that subjects were in "steady state" and because several weeks are necessary to obtain the full antidiabetic effect of the TZDs. The expression of genes involved in glycerol-3-phosphate synthesis was increased after pioglitazone treatment. For example, PEPCK-C, an enzyme critical for glyceroneogenesis from pyruvate or lactate (17, 18) increased by 84% in TZDtreated subjects. A recent report shows that glyceroneogenesis is the main metabolic pathway supplying glycerol for triacylglycerol synthesis in fasted humans (19) . The higher mRNA level was also observed for GPDH after TZD treatment. In contrast, GyK, which has been proposed as an important enzyme for reesterification of glycerol in adipocytes and the reduction in circulating free fatty acids in rodents and in vitro experiments (20) , was unchanged by TZD treatment in the present study. This suggests that TZD upregulation of GyK is a transient effect or, alternately, may not be so important in human adipose tissue. Our observation is in accordance with a recent study showing that GyK is not induced by rosiglitazone in human adipocytes in vitro (21) . The changes in PEPCK-C and GPDH gene expression are consistent with the observed increase in insulin-stimulated fatty acid storage in rodent adipose tissue cultured in vitro (22) (23) (24) and the decrease in hepatic fat content (25, 26) seen with TZD treatment. In other words, higher uptake and storage of fatty acids in adipose tissue might prevent the delivery of fatty acids to liver and skeletal muscle (27, 28) , and our results demonstrate for the first time that PEPCK-C may be an important factor driving this process in human adipocytes in vivo. The expression of CAP, an important component of the alternate insulinsignaling pathway required for GLUT-4 translocation and glucose uptake recently described (29, 30) , was higher after pioglitazone treatment, as observed in our study, in 3T3-L1 adipocytes, and in a rodent model in vivo (31, 32) . The action of TZDs to increase CAP might improve adipocyte insulin sensitivity and provide the glucose (9) necessary for the production of pyruvate/glycerol, which is finally converted into triglycerides (Fig. 3) .
The present study also shows robust changes in the expression of genes involved in the availability and synthesis/ storage of fatty acids. LPL mRNA and ACS mRNA increased after TZD treatment.
FAS mRNA also tended to increase. This is consistent with several previous in vitro and in vivo studies (24, 27, 33, 34) . A few genes previously reported to be responsive to TZDs, especially in an animal model or in an in vitro system, including ANGPTL-4, resistin, leptin, and 11␤ HSD (24, (35) (36) (37) , did not change after TZD treatment. Why these genes failed to respond to TZD treatment in vivo remains to be determined but may depend upon nuclear receptor cofactor recruitment or other unknown factors. Subtle changes in the conformation of PPAR-␥ determine the set of genes transcribed after ligand binding, and these may somehow be different when comparing in vivo versus in vitro. There was no relation between the magnitude of the change in gene expression (LPL, CAP, FAS, etc.) and the magnitude of the change in clinical phenotypes such as HbA 1c , body weight, and fasting glucose.
As previously reported, TZDs cause a modest weight gain in patients that cannot be explained by differences in resting energy expenditure or the thermic effect of food (15) . Newer PPAR-␥ agonists that dissociate the insulin-sensitizing effects from the lipogenic/adipocyte differentiation effects may allow us to determine whether the lipogenic actions of TZD are necessary for the complete insulinsensitizing effects seen with current TZDs. Until then, these studies suggest that increased lipid storage in adipose tissue may be one mechanism by which TZD sequesters lipids in adipose tissue, increases body weight, and improves insulin sensitivity in vivo. In the absence of histological data, it is possible that some of the observed effects may be due to an altered ratio of fully differentiated adipocytes to other cell types (or small insulinsensitive cells), thereby leading to the observed effects.
Next, we investigated the relationship between PPAR-␥ mRNA and expression of our genes of interest. The expression of several genes was highly correlated with PPAR-␥1 and/or PPAR-␥2 expression before TZD treatment. This observation can be interpreted in at least two ways. First, the expression of PPAR-␥1/PPAR-␥2 might directly lead to increased PPAR-␥ protein and gene expression of CAP, LPL, ACS, GyK, 11␤ HSD 1, FAS, and GPDH. An alternate explanation is that a common transcription factor drives both PPAR-␥1/PPAR-␥2 and these same genes. These strong relationships of mRNA for certain genes (LPL, CAP, ACS) with PPAR-␥ mRNA suggest that the regulation of PPPAR-␥ mRNA is an important control point in vivo. Several other genes that have been demonstrated to be "TZD responsive" in vitro were not correlated with PPAR-␥ mRNA at baseline in our study. Specifically, ANGPTL-4 and PEPCK-C were not correlated to PPAR-␥1 mRNA, although it was previously reported that each can be upregulated by agonists for PPAR-␥ (23, 35) .
Interestingly, the expression of FAS, GPDH, and ACS, three genes critical for fatty acid storage as triglycerides in adipose tissue, were highly correlated with each other and with PPAR-␥. This suggests an important coordinate transcriptional control system for these lipogenic genes. One possible pathway includes activation of PPAR-␥ by pioglitazone, which contributes to the increased glucose uptake by fat cells (higher CAP, GLUT-4, and signaling molecules in the insulinsignaling pathway [our results, 38, 39] ) that are finally incorporated into triglycerides (Fig. 3) .
PPAR-␥ has been suggested as an important determinant of body weight based on studies in individuals with activating or inhibitory mutations of PPAR (40, 41) . We showed that neither PPAR-␥1 nor PPAR-␥2 mRNA was altered by TZD treatment, and our results are in agreement with others (9), suggesting that TZD effects possibly occur through activation of PPAR-␥ transcription and not through upregulation of the receptor expression (2).
In conclusion, 3 months of treatment with pioglitazone increased body weight, and this may be associated with upregulation of some, but not all, genes previously demonstrated as "TZD responsive" in abdominal subcutaneous adipose tissue. Combined with previous studies showing an increase in insulin-stimulated fatty acid uptake in adipose tissue and the weight gain commonly seen with TZDs in the clinical setting, these results suggest that TZDs might increase body weight through the upregulation of genes of adipocyte lipid storage pathways in vivo, including PEPCK-C, GPDH, and ACS.
